Pfizer’s Dividend Commitment Amid Challenges | Business and Finance News

Pfizer is doubling down on shareholder returns, confidently pledging to keep its massive $10 billion annual dividend steady despite earnings pressure — thanks to strong cash flow from operations and a strategic cash boost from selling long-term investments. Facing headwinds from expiring patents and a sluggish blockbuster pipeline, especially in the hot weight-loss space, the company’s agility shines: they pivoted by acquiring a promising drug candidate after their own faltered, and multiple other therapies are advancing. With deep cash reserves and strategic flexibility, Pfizer’s track record suggests they’re not just surviving — they’re adapting to keep investors rewarded. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6277f5ce0b23d74b